Arcturus Therapeutics (NASDAQ:ARCT) released its quarterly earnings data on Wednesday. The biotechnology company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.04, MarketWatch Earnings reports. The business had revenue of $3.42 million during the quarter, compared to analysts’ expectations of $3.75 million.
NASDAQ:ARCT traded down $0.15 on Friday, reaching $7.01. The stock had a trading volume of 7,600 shares, compared to its average volume of 40,906. The firm has a market cap of $76.60 million, a price-to-earnings ratio of -1.99 and a beta of 1.79. Arcturus Therapeutics has a 12-month low of $4.78 and a 12-month high of $11.48.
ARCT has been the topic of several recent research reports. Brookline Cap M reiterated a “buy” rating on shares of Arcturus Therapeutics in a research report on Thursday, September 27th. ValuEngine lowered shares of Arcturus Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, October 8th. Zacks Investment Research upgraded shares of Arcturus Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, August 1st. Finally, WBB Securities upgraded shares of Arcturus Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, September 20th. Two equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. Arcturus Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $12.00.
About Arcturus Therapeutics
Arcturus Therapeutics Ltd., an RNA medicines company, develops nucleic acid medicines to treat diseases with unmet medical needs. Its RNA therapeutics platforms could be applied in various types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA, and gene editing therapeutics.
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.